REVOLUTION MEDICINES INC (RVMD) Stock Price & Overview
NASDAQ:RVMD • US76155X1000
Current stock price
The current stock price of RVMD is 99.12 USD. Today RVMD is up by 0.49%. In the past month the price decreased by -0.52%. In the past year, price increased by 216.48%.
RVMD Key Statistics
- Market Cap
- 19.643B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.91
- Dividend Yield
- N/A
RVMD Stock Performance
RVMD Stock Chart
RVMD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 96.63% of all stocks.
RVMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVMD. RVMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RVMD Earnings
RVMD Forecast & Estimates
27 analysts have analysed RVMD and the average price target is 136.84 USD. This implies a price increase of 38.06% is expected in the next year compared to the current price of 99.12.
For the next year, analysts expect an EPS growth of -26.4% and a revenue growth 1132.72% for RVMD
RVMD Groups
Sector & Classification
RVMD Financial Highlights
Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -5.91. The EPS decreased by -65.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.05% | ||
| ROE | -69.35% | ||
| Debt/Equity | 0.16 |
RVMD Ownership
RVMD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RVMD
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
IPO: 2020-02-13
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA 94063 US
CEO: Mark A. Goldsmith
Employees: 883
Phone: 13026365400
REVOLUTION MEDICINES INC / RVMD FAQ
What does REVOLUTION MEDICINES INC do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
What is the current price of RVMD stock?
The current stock price of RVMD is 99.12 USD. The price increased by 0.49% in the last trading session.
What is the dividend status of REVOLUTION MEDICINES INC?
RVMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of RVMD stock?
RVMD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of RVMD stock?
REVOLUTION MEDICINES INC (RVMD) operates in the Health Care sector and the Biotechnology industry.
Who owns REVOLUTION MEDICINES INC?
You can find the ownership structure of REVOLUTION MEDICINES INC (RVMD) on the Ownership tab.